Infliximab

Withdrawal and reinitiation of treatment with most biologic agents had minimal impact on efficacy in plaque psoriasis, according to a study.

Therapeutic drug monitoring, in which serum levels are regularly checked to adjust dose and intervals, is more effective at controlling disease than standard therapy with infliximab, according to data presented at ACR Convergence 2021.

LAS VEGAS – Physicians should remember there are many points to consider when selecting the right treatment for patients with ulcerative colitis, according to a presenter at the ACG Annual Scientific Meeting.

Higher visceral adipose tissue correlated with lower rates of inflammatory bowel disease remission among patients dosed with infliximab, vedolizumab or ustekinumab, according to Andres Yarur, MD, Medical College of Wisconsin.

Patients with inflammatory bowel disease who switched from one infliximab biosimilar to another had no significant change in disease activity, according to research published in Alimentary Pharmacology and Therapeutics.

Methotrexate increases the probability of remission with adalimumab or infliximab by 50% in patients with psoriatic arthritis, versus TNF-inhibitor monotherapy, according to data published in the Annals of the Rheumatic Diseases.

Biologic infusions administered at home are associated with a 25% increased risk for hospital admission the same or next day, and a 28% higher risk for permanent discontinuation, compared with facility-given infusions, according to data.

On May 11, Icelandic-based drug developer Alvotech filed a lawsuit against AbbVie seeking to undo what it alleges is a “minefield” of “invalid” patents surrounding what is arguably the pharma giant’s most prized possession: Humira.

Researchers identified novel candidate biomarkers for infliximab response after unsupervised plasma proteomic analysis in pediatric patients with Crohn’s disease, according to a presentation at Digestive Disease Week.

Patients who are immunosuppressed will “likely” need regular COVID-19 vaccine boosters in the future, according to Jeffrey R. Curtis, MD, MS, MPH, chair of the American College of Rheumatology COVID-19 Vaccine Clinical Guidance Task Force.